The immunofluorescence (IF) staining and immunoblotting of the clinical PCa marker alpha-methylacyl-CoA racemase (AMACR)17 in BPH and PCa primary cells showed varying degrees of malignancy matched to the clinical pathology grade (Fig. 1d and Supplementary Fig. 1a). Here, AMACR is linked to benign prostatic hyperplasia.